Merck's cholesterol pill clears the FDA — the first you can swallow, not inject

Biotech & Longevity 4 min 80 sources

A drug class proven for a decade finally comes as a once-a-day tablet. Plus: a gentler prostate treatment matches surgery, an oral psoriasis pill, and a vaccine aimed at stopping pancreatic cancer before it starts.

Key takeaways

The FDA approved Merck's Lipfendra, the first cholesterol drug of its kind you can take as a daily pill instead of an injection — cutting LDL by nearly 60%, at about $315 a month.
A 10-year study found a gentler, targeted prostate treatment matches surgery or radiotherapy with less than half the side effects — yet only about 1,000 men a year in the UK get it.
An early vaccine aimed at preventing pancreatic cancer, not treating it, triggered the intended immune response in 90% of high-risk volunteers — a first, small step.

The US drug regulator, the FDA, approved a new cholesterol drug from Merck on Wednesday. On paper it is not a new idea. What is new is the shape it comes in: a pill [24].

The drug, sold as Lipfendra (also called enlicitide), blocks a protein called PCSK9. When that protein runs high, it drives up LDL — the “bad” cholesterol that hardens into plaque in the arteries and leads to heart attacks and strokes. Blocking it works, and we have known that for years. Drugs that hit PCSK9 have been on the market for about a decade. The catch: they were injections, given every few weeks. Lipfendra is the first one you can take as a once-daily tablet [24].

The numbers are strong. In late-stage trials the pill cut LDL by nearly 60% [24]. Merck says it carries no contraindications and no allergy warnings, unlike the injected versions [24]. About one in four US adults has high LDL, so the pool of people this could reach is enormous [24]. The list price is $10.50 a day — around $315 a month [24]. That last number matters as much as the science: a pill only helps the people who can get it and keep taking it. The trials so far measured cholesterol, the marker; the harder test — does it cut actual heart attacks and deaths over years — is what fully settles a drug like this.

Less harm for the same result

Two other stories this week share a quiet theme: treatments that do the job with less collateral damage.

A 10-year NHS study, led by Imperial College London and following nearly 3,500 men, found that “focal therapy” for prostate cancer works about as well as removing or irradiating the whole gland — but with less than half the risk of side effects like incontinence and loss of sexual function [43]. Focal therapy uses high-intensity ultrasound or freezing to destroy only the cancerous patch, not the entire prostate. Most of the men had intermediate- or high-risk cancer, yet 10 years on only two had died of the disease [43]. The technique has existed for more than 20 years, but only about 1,000 men a year in the UK receive it — the long-term data regulators wanted was, until now, missing [43].

On a smaller scale, Takeda reported strong phase 3 results for zasocitinib, an oral psoriasis pill, clearing the skin at hard-to-treat sites like the scalp, palms and nails — 77% and 74% of scalp-psoriasis patients responded across two trials [3]. Phase 3 is the large, final test before approval. A daily pill that reaches the stubborn spots is the kind of ordinary progress that rarely makes headlines and quietly changes lives.

Playing the longer game

The most striking work this week is aimed not at treating disease but at heading it off.

Researchers reported the first clinical milestone for a vaccine meant to prevent pancreatic cancer — one of the deadliest cancers, usually caught too late. It targets common mutations in a gene called KRAS that drive the tumour. In an early (phase 1) trial in people at high risk, the vaccine was safe and triggered the intended immune response in 90% of participants [46]. This is a first step, not a cure: phase 1 tests safety in a small group, and preventing cancer is far harder to prove than shrinking one. But the logic is sound — stop the disease before it starts.

In the same spirit, a mouse study offered a fresh angle on ageing. As we get older, worn-out “zombie” cells — senescent cells that have stopped dividing but leak inflammation — pile up because the body clears them more slowly. Rather than killing those cells directly, the researchers restored the body’s own disposal system; the treated mice held onto sharper minds and less frailty [53]. The caution is the usual one, and it is not small: this was in mice, and most things that work in mice never work in people.

Money moved too. The biotech Avere went public through a reverse merger and locked in a Chinese-developed anti-inflammatory drug in a deal worth up to $2.3 billion — a reminder that behind each of these results sits a bet someone is funding [40].

02 · Lesson · why it matters

The medicine that works is the one you'll actually take

A therapy already proven for a decade barely spread — not because it was weak, but because it came as a needle. The advance was making it easy.

The breakthrough that already happened

The science behind Merck’s new cholesterol pill is not new. Drugs that block PCSK9 — the protein that pushes bad cholesterol up — have been around for about ten years. They work. They cut the dangerous cholesterol hard, and the mechanism is well understood.

And yet they never spread the way their power suggested they would. They were injections. You needed a prescription hoop, a fridge, a needle every couple of weeks, and a bill your insurer often fought. So a drug that could help a very large number of people mostly helped a small one.

The new thing this week is not a better molecule. It is the same idea, made swallowable. The change worth noticing is not in the chemistry. It is in the distance between the medicine and the person.

Potency and friction are two different dials

Every treatment has two separate qualities, and we constantly confuse them.

One is potency: how much it does when someone actually takes it. The injections had this in full.

The other is friction: how hard it is to start it, stay on it, afford it, remember it, put up with it. This is the boring half, and it is usually the half that decides how much good a treatment does out in the world.

The mistake is to assume the two move together — that a more powerful drug helps more people. They don’t. Past a certain point, extra potency changes almost nothing, because the people who would benefit aren’t held back by a drug that’s too weak. They’re held back by one that’s too much trouble to take. Push hard on the potency dial and the real-world benefit barely moves. Turn down the friction dial — a pill instead of a shot — and it jumps.

The benefit you can’t feel loses to the cost you can

High cholesterol has a cruel design. It causes no symptoms. You feel exactly the same with dangerous arteries as with clean ones — right up until the day you don’t. The harm is silent, distant, and only probable.

Set that against the cost of preventing it. That cost is immediate and concrete: the injection, the co-pay, the errand, the small daily bother. So the mind does what minds do. It weighs a cost it can feel today against a benefit it cannot feel at all, and the benefit loses. This is not weakness. It is how attention works. We act on what reaches us.

That is why lowering friction can matter more than raising potency for anything built this way — a price paid now against a payoff that is invisible, far off, and merely likely. Cholesterol pills. Money set aside for old age. A seatbelt on a short drive. The thing that would help sits behind a small wall of bother, and the wall, not the thing, is what stops us. You know this from your own week: the good habit that lapsed did not fail because it stopped working. It failed because it asked slightly more than the moment wanted to give.

The wall we chose, and the one we didn’t

Not all friction is an accident of biology. Some of it is built.

The needle was chemistry’s fault. The $315-a-month price is not — it is a decision, and it is now the tallest part of the wall the pill still has to clear. One barrier came down this week; another was left standing. A cheaper injection would have helped more people than an expensive pill, and an expensive pill helps more than a cheaper injection nobody could be bothered to take. Form and price are both frictions, and they trade against each other in ways that have little to do with how good the drug is.

It is worth seeing that clearly, without deciding who to blame for it. The people who set the price are answering to costs and investors and the decade of failed drugs that paid for this one. The arrangement can be self-serving and still leave millions better off than before. Both things are true. The point is only that “how well it works” and “how many it reaches” are set by different people, at different tables, for different reasons.

What the seat can’t see

From where we sit, the molecule is the story. It is dramatic, it is measurable, it wins the headline and the share-price bump. The friction is mundane — a fridge, a co-pay, a Tuesday you forgot. So we reliably overrate the science and underrate the bother, and then we are surprised when a brilliant drug helps fewer people than a boring one.

You are inside this, not above it. You are one of the one-in-four with the silent risk, or you love someone who is, and the thing that will or won’t help you turns less on a laboratory than on a chain of small, dull obstacles no single person can see end to end — the chemist, the insurer, the pharmacy, your own tired evening. Seeing that the wall matters as much as the cure doesn’t make you master of it. It just makes the next confident claim — this changes everything — a little easier to hold loosely, until you know whether the thing that changed was the medicine, or the reach.

03 · Lab · your turn

The Reach, Not the Recipe

Rehearse how a treatment's form and price, not its raw power, decide how many people it actually helps.

04 · Hope · carry this

The hardest part of helping people is rarely the discovery. It is the slow, unglamorous work of making a proven thing easy enough to reach them — and this week that work moved, as a decade-old cure quietly became something as ordinary as a daily pill.